2010 is the fifth consecutive year in which Phenomenex has received this award, and two of the company’s products were recognized. Another award went to the company’s Kinetex® core-shell HPLC column technology.
According to bioseparations product manager Michael McGinley, “Clarity OTX removes a major roadblock in oligonucleotide drug development and there is nothing like it on the market. It’s a game-changing innovation.”
Unlike previous oligonucleotide therapeutic isolation techniques that use labor-intensive, low-throughput, liquid/liquid extraction methods, Clarity OTX isolates oligonucleotide therapeutics and their metabolites in just 15 minutes. Clarity OTX extraction kits effectively remove cell debris that can mask the oligo therapeutic or metabolite of interest and interfere with low-level MS detection.
“The R&D 100 Awards have always represented some of the most innovative concepts to reach the marketplace in the past year. 2010 is no exception, and we had a particularly strong field of entries for the judges to evaluate,” said Rita Peters, editorial director of R&D Magazine.
R&D 100 award winners will be recognized at the annual banquet on November 11, 2010 in Orlando, Fla.
About Phenomenex
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, government and academic laboratories. From drug discovery and pharmaceutical development to disease diagnosis, food safety to environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com.
